The Filing Desk

Anika Therapeutics

ANIK · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

ANIK · Last close · November 19, 2026
$13.28
Value Anika Therapeutics yourself

Anika Therapeutics' revenue fell 5.9% to $113 million in fiscal 2025. Its operating margin was −9.8%, down from −4.2% a year earlier. Free cash flow was $4 million. It paid out $9 million in dividends and buybacks, 217% of free cash flow. The diluted share count fell 2.6%.

Anika Therapeutics, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 3, 2026 · 0001171843-26-001275 Updated
Revenue
$113M
5.9%
Operating margin
−9.8%
5.6 pts
Net income
−$11M
 
Free cash flow
$4M
 
Return on equity
−7.3%
23.5 pts
Market cap
$178M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Anika Therapeutics does

Anika makes medical products from hyaluronic acid, a substance found naturally in the body's joints and tissues. Its products go to orthopedic surgeons and other physicians, mainly to treat joint pain and to repair tendons and cartilage.

It reports two product groups. Osteoarthritis pain management includes Monovisc and Orthovisc, which are injections for joint pain, and Cingal. Regenerative solutions includes the Integrity Implant System, a scaffold used in rotator cuff and other tendon repairs, and Hyalofast, which is awaiting FDA approval. The company lists competition as a risk.

In October 2024 the company decided to focus on these two groups. It sold its Arthrosurface business in October 2024 and its Parcus Medical business in March 2025. It filed an application with the FDA for Hyalofast in October 2025 and is working on a response to the deficiencies the FDA listed in January 2026. At the end of 2025 it had 235 full-time employees in the United States and Europe.

Its biggest risks, as it describes them

  • Relying on a small number of customers for much of its osteoarthritis pain management revenue.
  • Approval of Hyalofast and Cingal in the U.S. is uncertain, and the FDA has already listed deficiencies for Hyalofast.
  • Relying on a small number of suppliers for key raw materials and components.
  • Disruption to its manufacturing, and product liability claims if its products harm patients.
From Anika Therapeutics's annual report on Form 10-K, filed March 3, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2021, earnings per share fell 33.5% a year and net income 33.9% a year, while buybacks cut the share count by 3%. Anika Therapeutics then lost money in fiscal 2022, 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments124121957981
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio5.7x6.1x5.3x4.9x4.7x
Quick ratio4.5x4.7x4.5x3.9x3.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Anika Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $264,308 of Anika Therapeutics shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 4, 2026Gary P FischettiDirectorBought1,000$20.32$20,320Form 4
Aug 3, 2026Gary P FischettiDirectorBought1,000$20.75$20,750Form 4
May 1, 2026John B Henneman IIIDirectorBought5,000$14.66$73,300Form 4
Apr 30, 2026Stephen D. GriffinPresident and CEO, DirectorBought12,200$12.29$149,938Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 400.1%−2.7%−2.0%
Altman Z''8.597.226.68
Accruals ratio−26.1%−26.1%−11.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailPassPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailFail
Share count didn't risePassFailPass
Gross margin rosePassFailFail
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Anika Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Anika TherapeuticsFY25−5.9%−9.8%3.9%———
OraSure TechnologiesFY25−38.1%−62.6%−46.3%———Compare
Outset MedicalFY255.1%−55.8%−39.4%−88.0%—6Compare
OwletFY2535.4%−7.8%−10.5%——5Compare
Sanara MedTechFY2519.0%7.1%2.1%13.0%2.6x3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue103113106115130148114121120113
Revenue growth11.2%9.7%−6.9%8.6%13.8%13.3%−23.0%6.1%−0.7%−5.9%
Gross profit79867486698373827664
Research and development11191817232718222626
Operating income51462234−28341−5−11
Net income32321927−244−15−83−56−11
Diluted EPS (US$)2.152.111.271.89−1.690.28−1.02−5.64−3.83−0.76
Diluted shares (millions)15151514141515151514
Cash flow
Cash from operations244135371384−2511
Capital expenditure14953258587
Free cash flow10323034113−3−7−24
Dividends paid0000000000
Share buybacks250303000051110
Acquisitions00009500000
Stock-based compensation3611651114151310
Balance sheet at fiscal year end
Cash and short-term investments12515715918598124121957981
Debt incl. finance leases——————————
Total assets240283279331366348349271203190
Total liabilities18191542936064584947
Shareholders' equity223264264288272287286212154144
Margins and ratios
Gross margin76.8%75.9%70.4%74.9%52.9%56.1%64.3%68.3%63.4%56.6%
Operating margin49.0%40.3%20.6%29.9%−21.7%1.8%3.2%0.7%−4.2%−9.8%
Net margin31.5%28.1%17.7%23.7%−18.4%2.8%−13.1%−68.4%−47.0%−9.6%
Free cash flow margin10.1%28.1%28.7%29.8%8.8%2.2%−2.7%−6.0%−1.9%3.9%
Rule of 40 (growth + FCF margin)21.2%37.8%21.7%38.4%22.6%15.5%−25.7%0.1%−2.7%−2.0%
Return on capital——————————
Return on equity15.0%13.1%7.1%9.8%−8.6%1.5%−5.2%−33.2%−30.8%−7.3%
Return on assets13.7%12.2%6.7%8.9%−6.9%1.2%−4.3%−26.7%−23.8%−5.5%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Anika Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Anika Therapeutics.